Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples